SWX:IDIABiotechs
Idorsia’s Quvivic Traction And Pipeline Progress Reshape Growth Outlook
Idorsia reports recent commercial traction for its insomnia drug Quvivic, including broader public reimbursement across major European and North American markets.
The company highlights plans for further international rollout of Quvivic and updates on late stage pipeline assets, including pediatric studies.
Partnered programs are progressing clinically, with collaborations moving forward alongside Idorsia’s own R&D efforts.
Idorsia (SWX:IDIA) is drawing attention as it updates investors on...